2. Novartis and Antisoma

Who: Novartis
With: Antisoma
What: $890 million licensing deal

Summary: With money from the sale of two major divisions burning a hole in its pocket, Novartis inked a massive deal for the worldwide rights to Antisoma's AS1404, a lung cancer therapy currently in mid-stage testing. Novartis agreed to pay up to $890 million for the drug. Antisoma’s presentation of positive Phase II results involving patients with non-small cell lung spurred Novartis into snapping up the drug. In addition, data from other Phase II trials in ovarian and prostate cancers indicate increased response rates through the addition of AS1404 to standard chemotherapy. Release

Related Articles:
Novartis inks $890M cancer therapy deal. Report
Antisoma trial delivers positive returns. Report
Antisoma drug flunks ovarian cancer trial. Report

2. Novartis and Antisoma

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.